Dive Brief:

简报：

Vor Biopharma is

沃尔生物制药是

licensing rights

许可权利

to an immune disease drug from Chinese biotechnology company RemeGen, it said Wednesday, a little over one month after

中国生物技术公司荣昌制药周三表示，其免疫疾病药物已获批准，此时距离上个月底仅过去一个多月。

announcing plans

宣布计划

to review strategic alternatives.

审查战略替代方案。

As part of its shift in focus, Vor also announced it appointed former MorphoSys leader Jean-Paul Kress as CEO. Vor’s previous chief executive Robert Ang will stay on as an adviser through October.

作为其关注重点转移的一部分，Vor还宣布任命前MorphoSys首席执行官Jean-Paul Kress为新任CEO。Vor的前首席执行官Robert Ang将留任顾问至十月。

Vor also

前进，所以

raised $175 million

筹集了1.75亿美元

in a PIPE, or private investment in public equity, that involved

在PIPE，即公共股权的私人投资中，涉及到了

half a dozen investors

六位投资者

including RA Capital Management, Forbion and Venrock Healthcare Capital Partners.

包括RA资本管理公司、Forbion和Venrock医疗资本合作伙伴。

Dive Insight:

深度洞察：

PureTech Health and the oncologist and author Siddhartha Mukherjee founded Vor

PureTech Health 与肿瘤学家兼作家 Siddhartha Mukherjee 共同创立了 Vor。

nearly a decade ago

将近十年前

. Progress developing a treatment for leukemia led the company in 2021 to

. 白血病治疗的进展使该公司在2021年

price a $177 million initial public offering

定价为1.77亿美元的首次公开募股

.

。

But a rocky few years forced Vor to change direction. The Cambridge, Massachusetts-based biotech

但是，艰难的几年迫使沃尓改变了方向。这家位于马萨诸塞州剑桥市的生物技术公司

had been advancing

一直在前进

cell therapies called trem-cel and VCAR33, but

细胞疗法称为 trem-cel 和 VCAR33，但是

in May

五月

revealed plans to wind down clinical operations and lay off 95% of its employees.

透露了缩减临床业务并裁员95%的计划。

Now, Vor is reestablishing itself as an autoimmune disease company. The deal with RemeGen gives its rights to develop and commercialize in most parts of the world a drug for generalized myasthenia gravis, systemic lupus erythematosus and rheumatoid arthritis that’s already approved in China.

现在，Vor公司正在重新确立自身作为一家自身免疫疾病公司的定位。与荣昌生物（RemeGen）的交易使其获得了在世界大部分地区开发和商业化一种药物的权利，该药物针对全身性重症肌无力、系统性红斑狼疮和类风湿性关节炎，且已在中国获批。

Vor is paying RemeGene $45 million upfront along with $80 million in warrants to purchase common stock in exchange for the drug, called telitacicept.

Vor正在向RemeGene支付4500万美元的预付款以及8000万美元的认股权证，以购买名为telitacicept的药物。

Telitacicept is in Phase 3 testing for generalized myasthenia gravis in the U.S., Europe and South America, according to the companies. Data from that trial is expected in 2027.

据公司称，泰利西普正在美国、欧洲和南美进行针对全身性重症肌无力的三期试验，预计该试验的数据将在2027年公布。

“I am absolutely thrilled to be leading Vor Bio as we transform the company to become a major player in autoimmune disease treatment,” Kress said in a statement.

“我对我们正在将公司转型为自身免疫性疾病治疗领域的主要参与者感到无比激动，”克雷斯在一份声明中表示。

Telitacicept’s targets are cytokines known as BAFF and APRIL, which have also been the focus of

泰利西普的靶点是细胞因子，称为BAFF和APRIL，这些也是关注的焦点。

other dealmaking

其他交易谈判

.

。

Recently, China-based biotechs like RemeGen are providing

近日，像荣昌生物这样的中国生物技术公司正在提供

more and more of the drug candidates licensed by U.S.

越来越多的美国授权的药物候选者

and European drugmakers. “Global biopharma companies can increasingly look to China as a cost-effective source of innovation, particularly for validated targets and rapid generation of proof-of-concept data,” Leerink Partners analyst David Risinger wrote in a Thursday note to clients.

欧洲制药商。 “全球生物制药公司可以越来越多地将中国视为具有成本效益的创新来源，特别是对于已验证的目标和快速生成概念验证数据，” Leerink Partners 分析师 David Risinger 在周四致客户的一份报告中写道。

Vor’s decision to start anew with a Phase 3-ready drug candidate contrasts with the route preferred by some activist investors and analysts, who have pushed struggling biotechs to wind down and return cash to shareholders rather than try to reinvent themselves. Some, like

Vor决定用一个已准备好进入第三阶段的药物候选品重新开始，这与一些激进投资者和分析师偏好的路径形成对比，他们一直在推动陷入困境的生物技术公司停止运营并把现金返还给股东，而不是试图重塑自我。一些公司，像

Third Harmonic Bio

第三谐波生物

and

和

iTeos Therapeutics

iTeos治疗公司

, have taken this course, while

，已经选修了这门课程，而

others

其他

have resisted the pressure

顶住了压力

“I couldn't be more thrilled with this exciting new direction for Vor, and new leadership with the background and skills appropriate for this asset,” Ang, Vor’s former CEO, wrote in a

“我对Vor这一令人兴奋的新方向以及拥有适合该资产背景和技能的新领导层感到无比激动，”Vor前首席执行官Ang在一份文件中写道。

LinkedIn post

领英帖子

.

。

Shares in Vor nearly doubled on the news to trade around $1 apiece by Thursday afternoon.

沃勒公司的股价在周四下午因该消息几乎翻倍，涨至每股约1美元。